ATE:CC News and Press, Antibe Therapeutics Inc. From 04/01/24

Antibe Therapeutics Inc. (“Antibe” or the “Company” TSX: ATE, OTCQX: ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration (“FDA”) that otenaproxesul has been placed on clinical...

- The American Society of Regional Anesthesia and Pain Medicine is the largest subspecialty medical society in anesthesiology Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammatio...

- AAPM is the primary organization for pain medicine physicians in the U.S. Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, is pleased to announce a poster presentation of...

A look at the top 10 most actives in Canada Bitfarms Ltd. (BITF) fell 8.3% to $3.63 on volume of 14,141,773 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) rose 10.6% to $4.79 on volume of 13,314,563 shares New World Solutions Inc. (NEWS) rose 0.0% to $0.08 on volume of 12,587,0...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, today announced that the arbitrator has found in favor of Nuance Pharma in the dispute regarding the license agreement for the commer...

- Successful PK/PD study confirms liver safety, sets stage for upgraded Phase II trial launch next month - Phase II trial enhancements include placebo arm, increased sample size and adaptive design - Ended quarter with $25 million in cash and equivalents Antibe Therapeut...

Synex Renewable Energy Corporation (SXI:CA) is expected to report for Q2 2024 Dye & Durham Limited (DND:CA) is expected to report for Q2 2024 Economic Investment Trust Limited (EVT:CA) is expected to report for quarter end 2023-12-31 Western Forest Products Inc. (WEF:CA) is expect...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is extending the Early Warrant Exercise Incentive Program (“ Early Warrant Exercise Program ”...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce an Early Warrant Exercise Incentive Program (“ Early Warrant Exercise Program ...

- Completed successful PK/PD study for otenaproxesul’s new formulation - Phase II initiation on track for upcoming quarter - Ended quarter with $28 million in cash and equivalents Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology compan...